Fusion Antibodies plc

Notice of General Meeting to be held on 5 March 2024

Proxy Form 2024 General Meeting

Results of Annual General Meeting on 27 October 2023

Proxy Form 2023 Annual General Meeting

Notice of Annual General Meeting on 27 October 2023

Notice of General Meeting held on 8 June 2023

Proxy Form General Meeting held on 08 June 2023

Results of voting at Annual General Meeting on 23 September 2022

Proxy Form 2022 Annual General Meeting

Chairman's Letter (inc. Notice of AGM held on 23 September 2022)

Results of voting at Annual General Meeting on 24 September 2021

Chairman's Letter (inc. Notice of AGM held on 24 September 2021)

Proxy Form 2021 Annual General Meeting

Results of voting at Annual General Meeting on 25 September 2020

Proxy Form 2020 Annual General Meeting

Chairman's Letter (inc. Notice of AGM held on 25 September 2020)

Results of voting at 2020 General Meeting

Notice of General Meeting held on 15 May 2020 

Proxy Form 2020 General Meeting held on 15 May 2020

 Chairman's Letter (inc. Notice of AGM held on 20 September 2019)

Proxy Form 2019 Annual General Meeting 

Results of voting at 2019 Annual General Meeting

Chairman's Letter (inc. Notice of AGM held on 21 September 2018)

Results of voting at 2018 Annual General Meeting

Shareholder Information

Share Price

Corporate Governance

Advisers

Registrar & FAQs

AIM Rule 26

Board Profiles

Company Profile

Regulatory News

Updates

Company Presentations

Home

Lora

At 26 July 2024, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company

Includes 600,000 Ordinary Shares held by Walsh Strategic Management Limited, a company controlled by Colin Walsh and 1,400,000 Ordinary Shares held by Hamniv   (GP) Limited, a subsidiary of Crescent Capital NI Limited ("Crescent Capital"). Colin Walsh is the Chief Executive and founder of Crescent Capital, which is the fund manager for Crescent Capital III LP. Crescent Capital III LP separately holds 613,382 Ordinary Shares.

Excludes Ordinary Shares held by relatives of Simon Douglas.

Insofar as it is aware, as at 26 July 2024, 5.87% of the Company's securities is not in public hands.  

Restrictions in transfer of AIM securities

There are no restrictions on the transfer of the Company's ordinary shares.

The Company is subject to the provisions of the City Code on Takeover and Mergers.

Fusion Antibodies has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.

As at 26 July 2024, the number of shares in issue was 95,365,564.  The company does not hold any ordinary shares in treasury.

Investor documents available for download.